CL2013003078A1 - Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica - Google Patents
Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéuticaInfo
- Publication number
- CL2013003078A1 CL2013003078A1 CL2013003078A CL2013003078A CL2013003078A1 CL 2013003078 A1 CL2013003078 A1 CL 2013003078A1 CL 2013003078 A CL2013003078 A CL 2013003078A CL 2013003078 A CL2013003078 A CL 2013003078A CL 2013003078 A1 CL2013003078 A1 CL 2013003078A1
- Authority
- CL
- Chile
- Prior art keywords
- amide
- dimethylethyl
- thiazol
- pyrrolidin
- trifluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478572P | 2011-04-25 | 2011-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003078A1 true CL2013003078A1 (es) | 2014-05-30 |
Family
ID=46018130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003078A CL2013003078A1 (es) | 2011-04-25 | 2013-10-24 | Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica |
Country Status (25)
Country | Link |
---|---|
US (3) | US20140066474A1 (es) |
EP (1) | EP2701703A1 (es) |
JP (2) | JP6086902B2 (es) |
KR (1) | KR101925656B1 (es) |
CN (1) | CN103491955B (es) |
AR (1) | AR086481A1 (es) |
AU (2) | AU2012250010A1 (es) |
BR (1) | BR112013027486A2 (es) |
CA (1) | CA2833962A1 (es) |
CL (1) | CL2013003078A1 (es) |
CO (1) | CO6801759A2 (es) |
EA (1) | EA025948B1 (es) |
EC (1) | ECSP13012994A (es) |
GT (1) | GT201300263A (es) |
IL (1) | IL229008A (es) |
MA (1) | MA35038B1 (es) |
MX (1) | MX2013012385A (es) |
NZ (1) | NZ615593A (es) |
PE (1) | PE20140601A1 (es) |
SG (1) | SG193919A1 (es) |
TN (1) | TN2013000392A1 (es) |
TW (1) | TWI602567B (es) |
UA (1) | UA110961C2 (es) |
WO (1) | WO2012148846A1 (es) |
ZA (1) | ZA201306973B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2776026A1 (en) * | 2011-11-02 | 2014-09-17 | Novartis AG | 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases |
JP2016512835A (ja) * | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
WO2015073644A1 (en) * | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
CA2937504A1 (en) * | 2014-02-11 | 2015-08-20 | Novartis Ag | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
WO2015148626A1 (en) * | 2014-03-26 | 2015-10-01 | Millennium Pharmaceuticals, Inc. | Treatment of fibrotic disorders |
ES2929554T3 (es) * | 2014-10-03 | 2022-11-30 | Novartis Ag | Composiciones farmacéuticas que comprenden alpelisib |
US20160339030A1 (en) * | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
GB202010627D0 (en) * | 2020-07-10 | 2020-08-26 | Qbd (Qs-Ip) Ltd | Blocking method |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
EP0734389B1 (en) | 1993-12-17 | 2000-03-29 | Novartis AG | Rapamycin derivatives useful as immunosuppressants |
DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag | Rapamycinderivate |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
AR044519A1 (es) * | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
EP1962839A4 (en) * | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
MX2011004585A (es) * | 2008-10-31 | 2011-06-01 | Novartis Ag | Combinacion de un inhibidor de fosfatidilinositol-3-cinasa (p13k) y un inhibidor de mtor. |
-
2012
- 2012-04-23 US US14/113,316 patent/US20140066474A1/en not_active Abandoned
- 2012-04-23 MX MX2013012385A patent/MX2013012385A/es unknown
- 2012-04-23 PE PE2013002391A patent/PE20140601A1/es not_active Application Discontinuation
- 2012-04-23 KR KR1020137027718A patent/KR101925656B1/ko active IP Right Grant
- 2012-04-23 WO PCT/US2012/034647 patent/WO2012148846A1/en active Application Filing
- 2012-04-23 NZ NZ615593A patent/NZ615593A/en not_active IP Right Cessation
- 2012-04-23 EA EA201391565A patent/EA025948B1/ru not_active IP Right Cessation
- 2012-04-23 BR BR112013027486A patent/BR112013027486A2/pt not_active Application Discontinuation
- 2012-04-23 JP JP2014508463A patent/JP6086902B2/ja not_active Expired - Fee Related
- 2012-04-23 SG SG2013070461A patent/SG193919A1/en unknown
- 2012-04-23 CN CN201280020528.4A patent/CN103491955B/zh not_active Expired - Fee Related
- 2012-04-23 AR ARP120101389A patent/AR086481A1/es unknown
- 2012-04-23 AU AU2012250010A patent/AU2012250010A1/en not_active Abandoned
- 2012-04-23 MA MA36325A patent/MA35038B1/fr unknown
- 2012-04-23 EP EP12717568.5A patent/EP2701703A1/en not_active Withdrawn
- 2012-04-23 CA CA2833962A patent/CA2833962A1/en not_active Abandoned
- 2012-04-23 UA UAA201311138A patent/UA110961C2/uk unknown
- 2012-04-24 TW TW101114591A patent/TWI602567B/zh not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06973A patent/ZA201306973B/en unknown
- 2013-09-27 TN TNP2013000392A patent/TN2013000392A1/fr unknown
- 2013-10-21 IL IL229008A patent/IL229008A/en active IP Right Grant
- 2013-10-24 CL CL2013003078A patent/CL2013003078A1/es unknown
- 2013-10-24 CO CO13252726A patent/CO6801759A2/es not_active Application Discontinuation
- 2013-10-25 EC ECSP13012994 patent/ECSP13012994A/es unknown
- 2013-10-25 GT GT201300263A patent/GT201300263A/es unknown
-
2016
- 2016-04-14 AU AU2016202372A patent/AU2016202372B2/en not_active Ceased
- 2016-10-27 US US15/335,957 patent/US20170095463A1/en not_active Abandoned
- 2016-11-18 JP JP2016224893A patent/JP2017061527A/ja active Pending
-
2017
- 2017-09-26 US US15/715,865 patent/US20180085362A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003078A1 (es) | Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica | |
IL268984B (en) | Derivatives of oxyntomodulin and a pharmaceutical preparation containing them for the treatment of obesity | |
BR112014016287A2 (pt) | composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma | |
RS54476B1 (en) | DERIVATIVES 1 - ((5-HETEROARYLTHIAZOL-2-IL) AMINOCARBONYL) PYROLIDINE-2-CARBOXAMIDE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
BR112013023175A2 (pt) | composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
BR112013029999A2 (pt) | derivados de tiazol | |
BR112014005235A2 (pt) | composto heterocíclico, composição farmacêutica, agente profilático e/ou terapêutico, e, método para prevenir e/ou tratar uma doença neurológica central | |
CL2011001299A1 (es) | Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer. | |
BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
ES2654908T8 (es) | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica | |
IL259824B (en) | History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs | |
EA201391028A1 (ru) | Гиполипидемическое противодиабетическое средство | |
CL2014000149A1 (es) | Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex. | |
BR112012021476A2 (pt) | composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto | |
EP3069720A4 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). | |
CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
CL2013002193A1 (es) | Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno. | |
CL2014002576A1 (es) | Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k. | |
BR112012020629A2 (pt) | forma cristalina, e, método para a terapia de um distúrbio | |
AR082418A1 (es) | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |